Who owns BIOMARIN PHARMACEUTICAL?
- CUSIP Number: 09061gak7
Tip: Access positions for across all investors
Analyze quarterly positions in Biomarin Pharmaceutical with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Biomarin Pharmaceutical stock
Who bought or sold BIOMARIN PHARMACEUTICAL this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Tenor Capital Management | 112M | $109M | 0% | Jun 2026 |
|
| Oaktree Capital Management | 64M | $62M | 14% | Jun 2026 |
|
| Capstone Investment Advisors | 62M | $61M | 15% | Jun 2026 |
|
| Man Group | 49M | $48M | 0% | Jun 2026 |
|
| Camden Asset Management | 46M | $45M | 100% | Jun 2026 |
|
| Opti Capital Management | 28M | $27B | 0% | Jun 2026 |
|
| MacKay Shields | 26M | $26M | 0% | Jun 2026 |
|
| Jpmorgan Chase & Co | 23M | $22M | 100% | Jun 2026 |
|
| Verition Fund Management | 19M | $18M | 114% | Jun 2026 |
|
| Victory Capital Management | 17M | $17M | -3% | Jun 2026 |
|
| Thrivent Financial for Lutherans | 15M | $15M | -4% | Jun 2026 |
|
| Toronto-Dominion Bank | 14M | $13M | -32% | Jun 2026 |
|
| BlackRock | 12M | $11M | -77% | Jun 2026 |
|
| State Street Corporation | 12M | $11M | -10% | Mar 2026 |
|
| DeepCurrents Investment Group | 10M | $9.7M | 0% | Jun 2026 |
|
| Citigroup | 9.8M | $9.4M | 100% | Mar 2026 |
|
| Wellesley Investment Advisors | 9.6M | $9.4B | 140% | Jun 2026 |
|
| Daiwa Securities Group | 8.5M | $8.3M | 100% | Jun 2026 |
|
| Russell Investments | 7.3M | $7.1M | 5% | Jun 2026 |
|
| Bank of America Corporation | 7.0M | $6.8M | -18% | Jun 2026 |
|
| Royal Bank of Canada | 4.8M | $4.7M | -5% | Jun 2026 |
|
| State of Wisconsin Investment Board | 4.0M | $3.9M | 33% | Jun 2026 |
|
| Palisade Capital Management | 4.0M | $3.9M | 7% | Jun 2026 |
|
| Colony | 3.2M | $3.1M | -4% | Jun 2026 |
|
| Bnp Paribas Investment Partners | 2.9M | $2.8M | 0% | Jun 2026 |
|
| Conning | 2.7M | $2.6M | 0% | Jun 2026 |
|
| Lazard Asset Management | 2.5M | $24k | -89% | Jun 2026 |
|
| Jupiter Topco | 2.3M | $2.2M | 100% | Jun 2026 |
|
| Nomura Asset Management International | 2.0M | $1.9M | 5% | Jun 2026 |
|
| Henderson Group | 1.6M | $1.5M | 100% | Mar 2026 |
|
| Morgan Stanley | 1.6M | $1.5M | 47% | Mar 2026 |
|
| Wells Fargo & Company | 1.6M | $1.5M | -1% | Jun 2026 |
|
| Nykredit A/S | 1.5M | $1.5M | 100% | Jun 2026 |
|
| TD Asset Management | 400k | $390k | 100% | Jun 2026 |
|
| Sei Investments | 371k | $361k | 0% | Jun 2026 |
|
| Ubs Global Asset Management Americas | 300k | $292k | 100% | Jun 2026 |
|
| Wellington Management Company | 273k | $266k | -56% | Jun 2026 |
|
| Oppenheimer Asset Management | 173k | $168k | -2% | Jun 2026 |
|
| Raymond James Financial | 69k | $67k | -9% | Jun 2026 |
|
| UBS Group | 68k | $66k | 3% | Jun 2026 |
|
| Stephens | 54k | $53k | 0% | Jun 2026 |
|
| Steward Partners Investment Advisory | 52k | $51k | 0% | Jun 2026 |
|
| Leucadia National Corporation | 51k | $50k | 100% | Jun 2026 |
|
| Ameriprise Financial | 47k | $46k | -8% | Jun 2026 |
|
| Capital Investment Advisory Services | 43k | $42k | 0% | Jun 2026 |
|
| Mariner Wealth Advisors | 42k | $41k | 0% | Jun 2026 |
|
| Bnp Paribas Arbitrage, Snc | 36k | $35k | -90% | Jun 2026 |
|
| HPM Partners | 35k | $34k | 100% | Jun 2026 |
|
| William Blair $ Company | 19k | $19k | 0% | Jun 2026 |
|
| Wiley Bros.-aintree Capital | 18k | $18k | 0% | Jun 2026 |
|
| Balboa Wealth Partners | 14k | $14k | -56% | Jun 2026 |
|
| LPL Financial | 13k | $13k | -24% | Jun 2026 |
|
| HB Wealth Management | 11k | $11k | 0% | Jun 2026 |
|
| We Are One Seven | 10k | $9.7k | 100% | Jun 2026 |
|
| Davenport & Co | 10k | $976k | 0% | Jun 2026 |
|
| Cetera Investment Advisers | 10k | $9.7k | 0% | Jun 2026 |
|
| Us Bancorp | 5.0k | $4.9k | 0% | Jun 2026 |
|
Who sold out of Biomarin Pharmaceutical?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Millennium Management | Mar 2026 | 7.5M | $7.2M |
| Barclays | Mar 2026 | 1.2M | $1.1M |
| Jane Street | Mar 2026 | 1.0M | $965k |
| Kohlberg Kravis Roberts & Co | Mar 2026 | 534k | $515k |
| Mml Investors Services | Mar 2026 | 49k | $47k |